A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

[1] Solomkin JS(2003)Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 997-1005

[2] Mazuski JE(1993)Intraabdominal infections Clin Infect Dis 17 961-5

[3] Baron EJ(1975)The bacteriology of intra-abdominal infections Surg Clin North Am 55 1349-54

[4] Sawyer RG(1995)Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial Surgery 118 716-21

[5] Nathens AB(1996)Antibiotic-resistant enterococci and the changing face of surgical infections Arch Surg 131 338-42

[6] DiPiro JT(2003)Intensive care unit management of intra-abdominal infection Crit Care Med 31 2228-37

[7] Buchman T(2004)Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery Eur J Clin Microbiol Infect Dis 23 682-7

[8] Dellinger EP(1999)In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 738-44

[9] Jernigan J(2000)Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 19-36

[10] Gorbach S(2002)In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Antimicrob Agents Chemother 46 2595-601

[1] Solomkin JS(2003)Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 997-1005

[2] Mazuski JE(1993)Intraabdominal infections Clin Infect Dis 17 961-5

[3] Baron EJ(1975)The bacteriology of intra-abdominal infections Surg Clin North Am 55 1349-54

[4] Sawyer RG(1995)Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial Surgery 118 716-21

[5] Nathens AB(1996)Antibiotic-resistant enterococci and the changing face of surgical infections Arch Surg 131 338-42

[6] DiPiro JT(2003)Intensive care unit management of intra-abdominal infection Crit Care Med 31 2228-37

[7] Buchman T(2004)Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery Eur J Clin Microbiol Infect Dis 23 682-7

[8] Dellinger EP(1999)In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 738-44

[9] Jernigan J(2000)Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 19-36

[10] Gorbach S(2002)In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Antimicrob Agents Chemother 46 2595-601